{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:58Z","timestamp":1740135178978,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T00:00:00Z","timestamp":1533686400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12879-018-3309-0","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T12:16:39Z","timestamp":1533730599000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-5175","authenticated-orcid":false,"given":"Mohammad H.","family":"Al-Shaer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hazem","family":"Elewa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosra","family":"Alkabab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lama H.","family":"Nazer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott K.","family":"Heysell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,8]]},"reference":[{"key":"3309_CR1","unstructured":"World Health Organization. Global tuberculosis report 2015, 20th ed. World Health Organization. http:\/\/www.who.int\/iris\/handle\/10665\/191102 ."},{"key":"3309_CR2","volume-title":"IDF Diabetes Atlas, 7 ed","author":"International Diabetes Federation","year":"2015","unstructured":"International Diabetes Federation. IDF Diabetes Atlas, 7 ed. Brussels: International Diabetes Federation; 2015."},{"key":"3309_CR3","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/0962-8479(95)90529-4","volume":"76","author":"SJ Kim","year":"1995","unstructured":"Kim SJ, Hong YP, Lew WJ, et al. Incidence of pulmonary tuberculosis among diabetics. Tuber Lung Dis. 1995;76:529\u201333.","journal-title":"Tuber Lung Dis"},{"key":"3309_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/art.21705","volume":"55","author":"SS Jick","year":"2006","unstructured":"Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006;55:19\u201326.","journal-title":"Arthritis Rheum"},{"key":"3309_CR5","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1371\/journal.pmed.0050152","volume":"5","author":"CY Jeon","year":"2008","unstructured":"Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5:e152.","journal-title":"PLoS Med"},{"key":"3309_CR6","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1741-7015-9-81","volume":"9","author":"MA Baker","year":"2011","unstructured":"Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81.","journal-title":"BMC Med"},{"key":"3309_CR7","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S1473-3099(09)70282-8","volume":"9","author":"KE Dooley","year":"2009","unstructured":"Dooley KE, Chaisson RE. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis. 2009;9:737\u201346.","journal-title":"Lancet Infect Dis"},{"key":"3309_CR8","unstructured":"Melmed S, Polonsky KS, Larsen PR, Kronenberg HM. Williams textbook of endocrinology. Philadelphia: Elsevier Health Sciences; 2015."},{"key":"3309_CR9","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2165\/00003495-200363060-00002","volume":"63","author":"B Blomberg","year":"2003","unstructured":"Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs. 2003;63:535\u201353.","journal-title":"Drugs"},{"key":"3309_CR10","first-page":"S353","volume":"3","author":"P Chaulet","year":"1999","unstructured":"Chaulet P. Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities. Int J Tuberc Lung Dis. 1999;3:S353\u20137. discussion S81\u20137","journal-title":"Int J Tuberc Lung Dis"},{"key":"3309_CR11","first-page":"61","volume":"79","author":"B Blomberg","year":"2001","unstructured":"Blomberg B, Spinaci S, Fourie B, et al. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001;79:61\u20138.","journal-title":"Bull World Health Organ"},{"key":"3309_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF03261926","volume":"51","author":"M Dostalek","year":"2012","unstructured":"Dostalek M, Akhlaghi F, Puzanovova M. Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet. 2012;51:481\u201399.","journal-title":"Clin Pharmacokinet"},{"key":"3309_CR13","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1086\/507543","volume":"43","author":"HM Nijland","year":"2006","unstructured":"Nijland HM, Ruslami R, Stalenhoef JE, et al. Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis. 2006;43:848\u201354.","journal-title":"Clin Infect Dis"},{"key":"3309_CR14","first-page":"129723","volume":"2013","author":"SK Heysell","year":"2013","unstructured":"Heysell SK, Moore JL, Staley D, et al. Early therapeutic drug monitoring for isoniazid and rifampin among diabetics with newly diagnosed tuberculosis in Virginia, USA. Tuberc Res Treat. 2013;2013:129723.","journal-title":"Tuberc Res Treat"},{"key":"3309_CR15","doi-asserted-by":"publisher","first-page":"7707","DOI":"10.1128\/AAC.01067-15","volume":"59","author":"SE Medell\u00edn-Garibay","year":"2015","unstructured":"Medell\u00edn-Garibay SE, Cortez-Espinosa N, Mil\u00e1n-Segovia RC, et al. Clinical pharmacokinetics of rifampin in patients with tuberculosis and type 2 diabetes mellitus: association with biochemical and immunological parameters. Antimicrob Agents Chemother. 2015;59:7707\u201314.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"3309_CR16","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/dc16-S010","volume":"39","author":"Association AD. 7","year":"2016","unstructured":"Association AD. 7. Approaches to Glycemic Treatment. Diabetes Care. 2016;39(Suppl 1):S52\u20139.","journal-title":"Diabetes Care"},{"key":"3309_CR17","doi-asserted-by":"publisher","first-page":"263ra159","DOI":"10.1126\/scitranslmed.3009885","volume":"6","author":"A Singhal","year":"2014","unstructured":"Singhal A, Jie L, Kumar P, et al. Metformin as adjunct antituberculosis therapy. Sci Transl Med. 2014;6:263ra159.","journal-title":"Sci Transl Med"},{"key":"3309_CR18","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.tube.2014.10.013","volume":"95","author":"MJ Chang","year":"2015","unstructured":"Chang MJ, Chae JW, Yun HY, et al. Effects of type 2 diabetes mellitus on the population pharmacokinetics of rifampin in tuberculosis patients. Tuberculosis (Edinb). 2015;95:54\u20139.","journal-title":"Tuberculosis (Edinb)"},{"key":"3309_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1183\/09031936.00180612","volume":"42","author":"AS Albanna","year":"2013","unstructured":"Albanna AS, Smith BM, Cowan D, et al. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42:721\u201332.","journal-title":"Eur Respir J"},{"key":"3309_CR20","first-page":"CD009913","volume":"5","author":"CR Gallardo","year":"2016","unstructured":"Gallardo CR, Rigau Comas D, Valderrama Rodr\u00edguez A, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2016;5:CD009913.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"3309_CR21","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0011-393X(96)80018-X","volume":"57","author":"LX Zhang","year":"1996","unstructured":"Zhang LX, Kan GQ, Tu DH, Wan LY, Faruqi AR. Fixed-dose combination chemotherapy versus multiple, single-drug chemotherapy for tuberculosis. Curr Ther Res. 1996;57(11):849\u201356.","journal-title":"Curr Ther Res"},{"key":"3309_CR22","first-page":"185","volume":"21","author":"Z Zaka-Ur-Rehman","year":"2008","unstructured":"Zaka-Ur-Rehman Z, Jamshaid M, Chaudhry A. Clinical evaluation and monitoring of adverse effects for fixed multidose combination against single drug therapy in pulmonary tuberculosis patients. Pak J Pharm Sci. 2008;21:185\u201394.","journal-title":"Pak J Pharm Sci"},{"key":"3309_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.6061\/clinics\/2015(06)08","volume":"70","author":"JT Wu","year":"2015","unstructured":"Wu JT, Chiu CT, Wei YF, et al. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinics (Sao Paulo). 2015;70:429\u201334.","journal-title":"Clinics (Sao Paulo)"},{"key":"3309_CR24","first-page":"1029","volume":"6","author":"WJ Su","year":"2002","unstructured":"Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater\/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis. 2002;6:1029\u201332.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3309_CR25","first-page":"760","volume":"13","author":"A Bartacek","year":"2009","unstructured":"Bartacek A, Sch\u00fctt D, Panosch B, et al. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13:760\u20136.","journal-title":"Int J Tuberc Lung Dis"},{"key":"3309_CR26","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1001\/jama.2011.436","volume":"305","author":"C Lienhardt","year":"2011","unstructured":"Lienhardt C, Cook SV, Burgos M, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the study C randomized controlled trial. JAMA. 2011;305:1415\u201323.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"3309_CR27","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.2337\/dc16-S005","volume":"39","author":"Association AD. 2","year":"2016","unstructured":"Association AD. 2. Classification and Diagnosis of Diabetes. Diabetes Care. 2016;39(Suppl 1):S13\u201322.","journal-title":"Diabetes Care"},{"key":"3309_CR28","unstructured":"Global Laboratory Initiative. Mycobacteriology laboratory manual. 1st ed. Global Laboratory Initiative. World Health Organization: Geneva. 2014."},{"issue":"1","key":"3309_CR29","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s12879-017-2231-1","volume":"17","author":"MH Al-Shaer","year":"2017","unstructured":"Al-Shaer MH, Mansour H, Elewa H, Salameh P, Iqbal F. Treatment outcomes of fixed-dose combination versus separate tablet regimens in pulmonary tuberculosis patients with or without diabetes in Qatar. BMC Infect Dis. 2017;17(1):118.","journal-title":"BMC Infect Dis"},{"issue":"9","key":"3309_CR30","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T. Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis. 2013;208(9):1464\u201373.","journal-title":"J Infect Dis"},{"key":"3309_CR31","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12879-017-2226-y","volume":"17","author":"Y Alkabab","year":"2017","unstructured":"Alkabab Y, Keller S, Dodge D, Houpt ER, Staley D, Heysell SK. Early interventions for diabetes related tuberculosis associate with hastened sputum microbiological clearance in Virginia, USA. BMC Infect Dis. 2017;17:125.","journal-title":"BMC Infect Dis"},{"key":"3309_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S1472-9792(02)00053-7","volume":"83","author":"JM Gravendeel","year":"2003","unstructured":"Gravendeel JM, Asapa AS, Becx-Bleumink M, et al. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb). 2003;83:183\u20136.","journal-title":"Tuberculosis (Edinb)"},{"issue":"2","key":"3309_CR33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1128\/JCM.18.2.384-388.1983","volume":"18","author":"MA Morgan","year":"1983","unstructured":"Morgan MA, Horstmeier CD, DeYoung DR, Roberts GD. Comparison of a radiometric method (BACTEC) and conventional culture media for recovery of mycobacteria from smear-negative specimens. J Clin Microbiol. 1983;18(2):384\u20138.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"3309_CR34","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1378\/chest.116.3.726","volume":"116","author":"MS Al-Moamary","year":"1999","unstructured":"Al-Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acid-fast bacilli in sputum smears in pulmonary tuberculosis. Chest. 1999;116(3):726\u201331.","journal-title":"Chest"},{"issue":"10","key":"3309_CR35","first-page":"S231","volume":"3","author":"W Fox","year":"1999","unstructured":"Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946\u20131986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3(10):S231\u201379.","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-018-3309-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-018-3309-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T22:44:22Z","timestamp":1661726662000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-018-3309-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["3309"],"URL":"https:\/\/doi.org\/10.1186\/s12879-018-3309-0","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2018,8,8]]},"assertion":[{"value":"28 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This research was conducted in accordance with the Declaration of Helsinki and national and institutional standards, and it was approved by Hamad Medical Corporation institutional review board and was assigned the number 15190\/15. Participant consent was not necessary for this study as it was a retrospective charts review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"384"}}